MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

The primary objective of this double-arm, single-blinded, Phase II randomized study is to
compare the area under the curve (AUC) for the Oral Mucositis Daily Questionnaire (OMDQ)
mouth and throat soreness (MTS) question 2 (Q2) score over a one-month period in subjects
receiving the MucoLox formulation versus sodium bicarbonate rinse (as the control) for the
prevention of severe mucositis in subjects with head/neck cancer receiving radiation ±
chemotherapy. Secondary objectives include comparing the time to OMDQ MTS Q2 > 2 between the
two arms; estimating and comparing opioid use defined as the average morphine equivalent
daily dose (MEDD) at each clinic visit; assessing and comparing changes in the remaining OMDQ
questions longitudinally throughout study; evaluating and comparing the duration of symptom
relief in those who experience any degree of oral mucositis; evaluating and comparing the
frequency of delays in [chemotherapy and/or radiation] therapy throughout the study period;
and summarizing and comparing the prevalence and grade of oral mucositis at each clinic
visit. The safety objective is to summarize the rates of potential side effects related to
each oral formulation. A total of 60 eligible subjects will be enrolled and randomized in a
1:1 fashion to one of the treatment arms. Subjects on the control arm (sodium bicarbonate)
who experience severe mucositis will have the option to crossover to the Mucolox arm for an
additional 7 ± 2 days or until day 29 ± 5 days, whichever is longer.

Inclusion Criteria

Subjects must meet all of the following criteria:

1. Confirmed head/neck cancer scheduled to receive at least a 28-day course of radiation
to the head/neck area (radiation field must include at least one mucosal site within
the oral cavity space, oropharynx, hypopharynx or larynx). Subjects must be planned to
receive a minimum cumulative dose of 40 Gy and maximum dose of 72 Gy of radiation.
Subjects may or may not be scheduled to receive concomitant platinum-based
chemotherapy administered with radiation

2. At least 18 years of age

3. ECOG performance status less than or equal to 2 or Karnofsky performance score greater
than or equal to 70%.

4. Able and willing to complete OMDQ (Appendix A) as determined by the treating
Investigator

5. Able and willing to swish/spit the oral formulation as determined by the treating
Investigator

6. Able and willing to provide informed consent

Exclusion Criteria

Subjects must not meet any of the following criteria:

1. Receiving any other pharmacological treatment within 1 week of initiation of study
treatment for oral mucositis, excluding analgesics, antibiotics, antifungals, and
hydration for symptom management. Subjects must also agree to not use any other
mouthwash formulations to prevent or treat mucositis during the course of the study.

1. The subject's enrolling investigator must agree to not prescribe any other
mouthwash formulations to prevent or treat oral mucositis during
protocol-directed treatment (Note: subjects may receive standard of care
treatment if the subject develops oral mucositis and discontinues study treatment
[or may crossover to Arm A if randomized to Arm B]).

2. Subjects must also agree to not use any other mouthwash formulations to prevent
or treat oral mucositis during protocol-defined treatment.

i. Agents suggested to modify oral mucositis risk or course that are not allowed
include sodium bicarbonate, magic mouthwash formulations, amifostine, benzydamine,
cevimeline, glutamine rinse, topical GM-CSF, interleukin-11, chlorhexidine, hydrogen
peroxide, diphenhydramine, palifermin, pilocarpine, steroid rinses, sucralfate, and
various oral rinse medical devices

2. Untreated or unresolved oral infections, including oral candidiasis or active lesions
due to oral herpes simplex virus infection.

3. Signs and symptoms of any mouth and/or throat condition or active dental disease that
would impair the ability to administer the mouthwash and/or assess the development of
oral mucositis, as determined by the Investigator.

4. Presence of baseline grade > 1 oral mucositis per WHO criteria as determined by the
treating investigator

5. Receiving chronic immunosuppression as determined by the Investigator

6. Known hypersensitivity to any ingredients in the mouthwash formulations that may
result in anaphylaxis.

7. Use, or suspicion of use, of illicit drugs or substances (self-reported) that may, in
the opinion of the Investigator, have a reasonable chance of contributing to
non-compliance, opioid abuse, drug toxicity, and/or otherwise skewing the trial result